Effect of increased CRM 197 carrier protein dose on meningococcal C bactericidal antibody response

Clinical and Vaccine Immunology

Volumn 19, Issue 4, 2012, Pages 551-556

  Lee, Lucia H ^a   Blake, Milan S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; DIPHTHERIA TOXOID CRM197; DIPHTHERIA TOXOID CRM197 HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE; DIPHTHERIA TOXOID CRM197 MENINGOCOCCAL GROUP C CONJUGATE VACCINE; DIPHTHERIA TOXOID CRM197 PNEUMOCOCCAL CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNOGENICITY; INFANT; NEISSERIA MENINGITIDIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SERUM BACTERICIDAL ANTIBODY ASSAY; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; UPREGULATION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT SYSTEM PROTEINS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HAEMOPHILUS VACCINES; HUMANS; INFANT; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; RABBITS;

EID: 84859304241     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05438-11     Document Type: Article

References (53)

1. Barington T, Skettrup M, Juul L, Heilmann C. 1993. Non-epitopespecific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components. Infect. Immun. 61:432- 438.
2. Bigio M, et al. 1987. Conformational changes in diphtheria toxoids. Analysis with monoclonal antibodies. FEBS Lett. 218:271-276.
3. Black S, Eskola C, Whitney C, Shinefield H. 2008. Pneumococcal conjugate vaccine and pneumococcal common protein vaccines, p 531-567. In Plotkin SA, Orenstein WA, Offit PA (ed), Vaccines, 5th ed. Elsevier Inc., Philadelphia, PA.
4. Borrow R, et al. 2010. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin. Vaccine Immunol. 17:154-159.
5. Borrow R, et al. 2010. Optimisation of schedules for meningococcal serogroup C conjugate vaccines driven by new immunogenicity and epidemiological data, abstr. OM40. 17th Int. Pathog. Neisseria Conf.
6. Borrow R, Miller E. 2006. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev. Vaccines 5:851-857. (Pubitemid 46021061)
7. Broker M, Costantino P, Detora L, McIntosh ED, Rappuoli R. 2011. Biochemical and biological characteristics of cross-reacting material 197 (CRM(197)), a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. Biologicals 39:195-204.
8. Buttery JP, et al. 2005. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA 293:1751-1758.
9. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. 2010. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin. Vaccine Immunol. 17:840-847.
10. Centers for Disease Control and Prevention. 2010. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use. Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly. Rep. 59:273.
11. Chandran A, Watt JD, Santosham M. 2008. Haemophilus influenzae vaccines, p 157-176. In Plotkin SA, Orenstein WA, Offit PA (ed), Vaccines, 5th ed. Elsevier Inc., Philadelphia, PA.
12. Danilova E, Shiryayev A, Skogen V, Kristoffersen EK, Sjursen H. 2005. Short-term booster effect of diphtheria toxoid in initially long-term protected individuals. Vaccine 23:1446-1450. (Pubitemid 40164703)
13. Decker MD, Edwards KM, Bradley R, Palmer P. 1992. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J. Pediatr. 120:184 -189.
14. Diez-Domingo J, et al. 2010. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr. Infect. Dis. J. 29:148-152.
15. Diez-Domingo J, et al. 2009. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers receiving routine vaccinations in Spain, abstr. 908. 27th Annu. Meet. Eur. Soc. Paediatr. Infect. Dis.
16. FDA.2011. Meningococcal (groupsA,CYand W-135) oligosaccharide diphtheria CRM197 conjugate vaccine package insert. http://www.fda.gov/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201342.htm. Accessed 1 May 2011.
17. FDA. 2011. Pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) package insert. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/ucm201667.htm. Accessed 1 March 2011.
18. Food and Drug Administration. 2011. Vaccines and related biological products advisory committee meeting report, 6-7 April 2011. Center for Biologics Evaluation and Research, Food and Drug Administration, Washington, DC. http://www.fda.gov/AdvisoryCommittees/Committees MeetingMaterials/ BloodVaccinesandOtherBiologics/VaccinesandRelated BiologicalProductsAdvisoryCommittee/ucm241549.htm.
19. Goldblatt D, et al. 2010. Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. Pediatr. Infect. Dis. J. 29:401-405.
20. Goldblatt D, et al. 2006. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J. 25:312-319.
21. Halperin SA, et al. 2002. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study. Clin. Invest. Med. 25:243-251. (Pubitemid 36204019)
22. Indrawati L, et al. 2010. Development of an infant rhesus monkey model for preclinical evaluation of a novel 15-valent pneumococcal polysaccharide protein conjugate vaccine, abstr. 228. 7th Int. Symp. Pneumococci Pneumococcal Dis.
23. Insel RA. 1995. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann. N. Y. Acad. Sci. 754:35-47.
24. Jackson LJ, et al. 2009. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed Meningococcal ACWY conjugate vaccine in adolescents. Clin. Infect. Dis. 49:e1-e10.
25. Kitchin N, et al. 2006. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine 24:3964-3970.
26. Klugman KP, et al. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349:1341-1348. (Pubitemid 37186212)
27. Knuf M, Kowalzik F, Kieninger D. 2011. Comparative effects of carrier proteins on vaccine-induced immune response. Vaccine 29:4881-4890.
28. Lagos R, et al. 2009. Immunology of combining CRM(197) conjugates for Streptococcus pneumoniae, Neisseria meningitis and Haemophilus influenzae in Chilean infants. Vaccine 27:2299-2305.
29. Larrauri A, Cano R, Garcia M, Mateo S. 2005. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23:4097-4100. (Pubitemid 40814584)
30. MacLennan JM, et al. 2000. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 283:2795-2801. (Pubitemid 30387823)
31. Maiden MC, et al. 2008. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis. 197:737-743. (Pubitemid 351364476)
32. Miller E, Salisbury D, Ramsay M. 2001. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20(Suppl. 1):S58-S67. (Pubitemid 32925012)
33. Moss SJ, et al. 2010. Immunogenicity of a heptavalent conjugate pneumococcal vaccine administered concurrently with a combination diphtheria, tetanus, five-component acellular pertussis, inactivated polio, and Haemophilus influenzae type B vaccine and a meningococcal group C conjugate vaccine at 2, 3, and 4 months of age. Clin. Vaccine Immunol. 17:311-316.
34. Pappenheimer AM, Jr, Uchida T, Harper AA. 1972. An immunological study of the diphtheria toxin molecule. Immunochemistry 9:891-906.
35. Peeters CC, et al. 1991. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect. Immun. 59:3504-3510.
36. Porro M, Saletti M, Nencioni L, Tagliaferri L, Marsili I. 1980. Immunogenic correlation between cross-reacting material (CRM197) produced by a mutant of Corynebacterium diphtheriae and diphtheria toxoid. J. Infect. Dis. 142:716-724. (Pubitemid 11138425)
37. Public Health Agency of Canada. 2009. An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An advisory committee statement (ACS). Can. Commun. Dis. Rep. 35:1-40.
38. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. 2003. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326:365-366. (Pubitemid 36241472)
39. Rappuoli R. 1983. Isolation and characterization of Corynebacterium diphtheriae nontandem double lysogens hyperproducing CRM197. Appl. Environ. Microbiol. 46:560-564. (Pubitemid 13024763)
40. Richmond P, et al. 1999. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J. Infect. Dis. 179: 1569-1572. (Pubitemid 29246613)
41. Riddell A, et al. 2007. A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide-CRM197 with a meningococcal group C conjugate vaccine in healthy infants: challenge phase. Vaccine 25:3906 -3912.
42. Schmitt HJ, et al. 2007. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae- Neisseria meningitidis serogroup C conjugate vaccine. Clin. Vaccine Immunol. 14:426-434.
43. Schmitt HJ, et al. 2008. Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaPIPV- HBV/Hib vaccine in healthy infants. Vaccine 26:2242-2252.
44. Slack MH, et al. 2001. Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines. J. Infect. Dis. 184:1617-1620. (Pubitemid 33139751)
45. Southern J, et al. 2009. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin. Vaccine Immunol. 16:194-199.
46. Southern J, Crowley-Luke A, Borrow R, Andrews N, Miller E. 2006. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine 24:215-219. (Pubitemid 41753009)
47. Tejedor JC, et al. 2006. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr. Infect. Dis. J. 25:713-720. (Pubitemid 44162129)
48. Tejedor JC, et al. 2004. Immunogenicity and reactogenicity of a threedose primary vaccination course with a combined diphtheria-tetanusacellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr. Infect. Dis. J. 23:1109-1115. (Pubitemid 40812757)
49. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. 2004. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365-367. (Pubitemid 38970013)
50. Trotter CL, Maiden MC. 2009. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev. Vaccines 8:851-861.
51. U.S. Food and Drug Administration Center for Biologics Evaluation and Research. 2011. Menactra: summary basis of regulatory approval for use in children 9-23 months of age. http://www.fda.gov/BiologicsBlood Vaccines/Vaccines/ApprovedProducts/ucm176044.htm. Accessed 30 August 2011.
52. Weiss AA, Hewlett EL. 1986. Virulence factors of Bordetella pertussis. Annu. Rev. Microbiol. 40:661-686.
53. Wysocki J, et al. 2009. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr. Infect. Dis. J. 28:S77-S88.